Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Metabolic medicine

Acute Treatment and Emergency Management

At a Glance

A CPS1 deficiency hyperammonemic crisis requires immediate hospital treatment to protect the brain. Specialists provide emergency calories and ammonia-lowering medicines, then use hemodialysis or CRRT when ammonia is severe, rising quickly, or causing brain symptoms.

A hyperammonemic crisis is a medical emergency that requires immediate management by specialists. The goal of acute treatment is threefold: stop the production of new ammonia, strip existing ammonia from the blood, and prevent the body from breaking down its own tissues for fuel [1][2]. These treatments are directed by a metabolic or critical-care team.

Immediate Nutritional Actions

The moment a crisis is suspected and you have reached the hospital, the team will intervene to halt the body’s internal “waste production.”

  • Clinician-Directed Protein Restriction: The hospital will temporarily stop natural protein intake [1]. This is a time-limited emergency measure; caregivers should never indefinitely withhold protein at home without providing the specific emergency calories prescribed by their sick-day plan, as this can worsen the crisis.
  • Provide High Calories: To prevent catabolism—where the body breaks down its own muscle and releases even more ammonia—doctors provide high amounts of non-protein energy [3]. This is usually given as concentrated intravenous (IV) glucose (dextrose) and sometimes IV fats (lipids) [4][5].
  • Insulin Therapy: In the intensive care unit (ICU), doctors may selectively use an insulin infusion with intensive glucose monitoring to further signal the body to build tissue (anabolism) rather than break it down [6]. Protein is reintroduced under specialist guidance when the acute phase stabilizes.

Ammonia-Lowering Medications

Specialized medications work to bypass the blocked steps of the urea cycle.

  • Nitrogen Scavengers: Intravenous medications like sodium benzoate and sodium phenylacetate act as “sponges” that bind to nitrogen in the blood and allow it to be excreted through the urine [7][4]. These are given as an IV “loading dose” followed by a continuous infusion, directed by the hospital team. (Oral maintenance formulations, like phenylbutyrate, are used differently and dosing is individualized.)
  • Amino Acid Supplements: L-arginine and citrulline are often given via IV. In CPS1 deficiency, these help keep the rest of the urea cycle moving and support the production of other essential molecules [2][8].
  • Carglumic Acid (Carbaglu): While this is an established, life-saving treatment for NAGS deficiency [9], its routine usefulness in CPS1 deficiency is limited. Some specific CPS1 mutations might respond to it, but it should not be framed as a routine rescue treatment or a substitute for scavengers and dialysis. It is only used under strict specialist direction [10][11]. While waiting for genetic results, doctors may use it in specific situations [12].

When Dialysis is Necessary

If ammonia levels are extremely high, rising rapidly, or the patient has symptoms of severe brain swelling (encephalopathy), doctors use renal replacement therapy (dialysis) to physically filter the blood [13].

  • Indications: The decision to dialyze is individualized. While some centers may use examples like starting dialysis when ammonia exceeds 500 µmol/L (or lower, if the child is in a coma or deteriorating), there is no single universal threshold [14][15][16]. Dialysis decisions depend on age, rate of rise, symptoms, and response to scavengers. Never wait for a specific numerical threshold if your child is symptomatic or directed to the ER by your sick-day plan.
  • Methods:
    • Hemodialysis: The fastest way to remove ammonia, often used to clear the toxin quickly [17][13].
    • CRRT (Continuous Renal Replacement Therapy): A slower, steady form of dialysis used for patients who are too unstable for rapid hemodialysis or to prevent rebound hyperammonemia [14][18].

Reducing ammonia quickly and safely is the best way to protect your child’s brain and future neurological outcome [19][20][21][22].

Common questions in this guide

What is the first hospital treatment for a CPS1 deficiency ammonia crisis?
The hospital team temporarily stops natural protein under medical supervision and gives concentrated intravenous glucose, sometimes with intravenous fats, to provide energy. This helps prevent the body from breaking down muscle and making more ammonia. Protein is added back only when the acute crisis is stabilizing and the metabolic team directs it.
Which medicines are used to lower ammonia in CPS1 deficiency?
Intravenous sodium benzoate and sodium phenylacetate bind nitrogen so it can leave the body in urine. Intravenous arginine and citrulline may help the remaining urea-cycle reactions continue. The hospital team chooses the doses and gives the initial loading dose and ongoing infusion.
Is carglumic acid a standard emergency medicine for CPS1 deficiency?
No. Carglumic acid is an established treatment for NAGS deficiency, but it has limited routine use in CPS1 deficiency and may help only with certain mutations or situations. It should be used only by specialists and cannot replace ammonia-scavenging medicines or dialysis when those are needed.
When might a child with CPS1 deficiency need dialysis?
Dialysis may be needed when ammonia is extremely high, rising quickly, or causing severe brain effects such as encephalopathy, brain swelling, or coma. There is no single number that applies to every child; clinicians consider age, symptoms, how quickly ammonia is changing, and response to medicines. A symptomatic child needs urgent emergency care rather than waiting for a particular ammonia threshold.
How do doctors choose between hemodialysis and CRRT?
Hemodialysis removes ammonia fastest and is often used when the toxin must be cleared quickly. CRRT provides slower, continuous removal and may be chosen when a patient is too unstable for rapid hemodialysis or when the team is concerned about ammonia rising again. The critical-care team individualizes the choice.
Should I stop my child's protein at home during a suspected crisis?
Do not create an indefinite protein-free diet or delay emergency care. Follow the exact sick-day instructions from your metabolic team, including the prescribed emergency calories, and go to the hospital as directed. Protein restriction in a crisis is temporary and must be supervised by clinicians.
Why might insulin be used during a CPS1 deficiency crisis?
In the intensive care unit, doctors may use an insulin infusion with close glucose monitoring to encourage the body to build tissue instead of breaking down muscle. This is an individualized hospital treatment and is not something to start outside medical supervision.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the 'anabolic' protocol (calories and insulin) the ICU will use to stop our child's body from breaking down its own muscle?
  2. 2.If our child requires dialysis, do you recommend intermittent hemodialysis for speed or continuous therapy (CRRT) for stability?
  3. 3.How long will the hospital-directed temporary protein restriction last before we introduce a prescribed safe amount?
  4. 4.Are there center-specific ammonia thresholds your team uses to decide when to initiate dialysis?
  5. 5.How many hours do you expect it will take for the IV ammonia scavengers to reach their peak effect?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    A successful liver transplantation in a patient with neonatal-onset carbamoyl phosphate synthetase-1 deficiency.

    Arslan S, Kocaoğlu İ, Yaralı O, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2024; (37(10)):924-929 doi:10.1515/jpem-2024-0240.

    PMID: 39158197
  2. 2

    Citrulline in the management of patients with urea cycle disorders.

    Imbard A, Bouchereau J, Arnoux JB, et al.

    Orphanet journal of rare diseases 2023; (18(1)):207 doi:10.1186/s13023-023-02800-8.

    PMID: 37480106
  3. 3

    N-acetylglutamate synthase deficiency with associated 3-methylglutaconic aciduria: A case report.

    Selvanathan A, Demetriou K, Lynch M, et al.

    JIMD reports 2022; (63(5)):420-424 doi:10.1002/jmd2.12318.

    PMID: 36101823
  4. 4

    Normal Neurological Development During Infancy Despite Massive Hyperammonemia in Early Treated NAGS Deficiency.

    Reigstad H, Woldseth B, Häberle J

    JIMD reports 2017; (37()):45-47 doi:10.1007/8904_2017_13.

    PMID: 28275973
  5. 5

    First report of carglumic acid in a patient with citrullinemia type 1 (argininosuccinate synthetase deficiency).

    Kose E, Kuyum P, Aksoy B, et al.

    Journal of clinical pharmacy and therapeutics 2018; (43(1)):124-128 doi:10.1111/jcpt.12593.

    PMID: 28741715
  6. 6

    Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy.

    Raina R, Bedoyan JK, Lichter-Konecki U, et al.

    Nature reviews. Nephrology 2020; (16(8)):471-482 doi:10.1038/s41581-020-0267-8.

    PMID: 32269302
  7. 7

    Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: a multicentre retrospective study.

    Husson MC, Schiff M, Fouilhoux A, et al.

    Orphanet journal of rare diseases 2016; (11(1)):127 doi:10.1186/s13023-016-0513-0.

    PMID: 27663197
  8. 8

    Long-term survival of a patient with acute neonatal-onset metabolic encephalopathy with carbamoyl phosphate synthetase 1 deficiency.

    Imataka G, Ishii J, Ando Y, et al.

    European review for medical and pharmacological sciences 2020; (24(19)):10051-10053 doi:10.26355/eurrev_202010_23220.

    PMID: 33090410
  9. 9

    The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency.

    Singh RH, Bourdages MH, Kurtz A, et al.

    Orphanet journal of rare diseases 2024; (19(1)):168 doi:10.1186/s13023-024-03167-0.

    PMID: 38637895
  10. 10

    Precision medicine in rare disease: Mechanisms of disparate effects of N-carbamyl-l-glutamate on mutant CPS1 enzymes.

    Shi D, Zhao G, Ah Mew N, Tuchman M

    Molecular genetics and metabolism 2017; (120(3)):198-206 doi:10.1016/j.ymgme.2016.12.002.

    PMID: 28007335
  11. 11

    N-carbamoylglutamate-responsive carbamoyl phosphate synthetase 1 (CPS1) deficiency: A patient with a novel CPS1 mutation and an experimental study on the mutation's effects.

    Yap S, Gougeard N, Hart AR, et al.

    JIMD reports 2019; (48(1)):36-44 doi:10.1002/jmd2.12034.

    PMID: 31392111
  12. 12

    Novel compound heterozygote variants: c.4193_4206delinsG (p.Leu1398Argfs*25), c.793C > A (p.Pro265Thr), in the CPS1 gene (NM_001875.4) causing late onset carbamoyl phosphate synthetase 1 deficiency-Lessons learned.

    Lin HT, Enchautegui-Colon Y, Huang YR, et al.

    Molecular genetics and metabolism reports 2022; (33()):100942 doi:10.1016/j.ymgmr.2022.100942.

    PMID: 36466970
  13. 13

    Extracorporeal Ammonia Clearance for Hyperammonemia in Critically Ill Patients: A Scoping Review.

    Naorungroj T, Yanase F, Eastwood GM, et al.

    Blood purification 2021; (50(4-5)):453-461 doi:10.1159/000512100.

    PMID: 33279903
  14. 14

    Characteristics of continuous venovenous hemodiafiltration in the acute treatment of inherited metabolic disorders.

    Eminoğlu FT, Öncül Ü, Kahveci F, et al.

    Pediatric nephrology (Berlin, Germany) 2022; (37(6)):1387-1397 doi:10.1007/s00467-021-05329-9.

    PMID: 34693482
  15. 15

    The impact of ammonia levels and dialysis on outcome in 202 patients with neonatal onset urea cycle disorders.

    Hediger N, Landolt MA, Diez-Fernandez C, et al.

    Journal of inherited metabolic disease 2018; (41(4)):689-698 doi:10.1007/s10545-018-0157-4.

    PMID: 29520739
  16. 16

    Hyperammonemia in urea cycle disorders: A toxic metabolite for the brain.

    Kido J, Nakamura K

    Pediatrics international : official journal of the Japan Pediatric Society 2025; (67(1)):e70121 doi:10.1111/ped.70121.

    PMID: 40464331
  17. 17

    Perspective Article: Hyperammonemia without Liver Failure - Key Considerations for Intensivists.

    Gillis P, Gennart T, Blackman S, et al.

    Blood purification 2026; (55(8)):553-560 doi:10.1159/000551474.

    PMID: 41818408
  18. 18

    Continuous Renal Replacement Therapy for Acute Decompensation in Inborn Errors of Metabolism: Single-Center, Pediatric Cohort, 2014-2025.

    Akyüzlüer Güneş MS, Köse E, Eyduran E, et al.

    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2026; doi:10.1097/PCC.0000000000004043.

    PMID: 42725842
  19. 19

    Long-term outcome of urea cycle disorders: Report from a nationwide study in Japan.

    Kido J, Matsumoto S, Häberle J, et al.

    Journal of inherited metabolic disease 2021; (44(4)):826-837 doi:10.1002/jimd.12384.

    PMID: 33840128
  20. 20

    Efficacy of peritoneal dialysis in neonates presenting with hyperammonaemia due to urea cycle defects and organic acidaemia.

    Celik M, Akdeniz O, Ozgun N

    Nephrology (Carlton, Vic.) 2019; (24(3)):330-335 doi:10.1111/nep.13224.

    PMID: 29356227
  21. 21

    Urea cycle disorders in critically Ill adults.

    Long MT, Kruser JM, Quinonez SC

    Current opinion in clinical nutrition and metabolic care 2024; (27(2)):184-191 doi:10.1097/MCO.0000000000000992.

    PMID: 37938118
  22. 22

    Hyperammonemia, the Last Indication of High-Volume Hemodiafiltration in Adult and Children: A Structured Review.

    Redant S, Beretta-Piccoli X, Mugisha A, et al.

    Blood purification 2019; (48(4)):330-335 doi:10.1159/000501390.

    PMID: 31291618

This page is for informational purposes only and does not constitute medical advice. A suspected CPS1 deficiency crisis requires immediate emergency care directed by your metabolic team; follow your child's individualized sick-day plan and do not indefinitely withhold protein or change medicines without specialist guidance.

Get notified when new evidence is published on Carbamoyl-phosphate synthetase 1 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.